This site is intended for healthcare professionals
A new era for epidermolysis bullosa at EADV 2023

EADV Congress 2023: A new era for epidermolysis bullosa

Amryt Pharmaceuticals sponsored
Read time: 60 mins
Last updated: 15th Feb 2024
Published:15th Feb 2024

In the first half of the pre-recorded session and interviews at EADV 2023, Dr Alexander Nyström (University of Freiburg, Germany) and Dr Su Lwin (Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, UK) discuss experimental data and investigational therapies for epidermolysis bullosa (EB).

Drivers for disease

Dr Nyström discusses the rationale behind his research on recessive dystrophic EB (RDEB), how results from these studies can inform clinical studies, and why understanding such experimental data is useful for clinicians. He also describes expectations for other subtypes of EB.

Dr Nyström started the session discussing drivers of EB, covering preclinical research into the role of collagen VII and fibrosis in RDEB and mechanisms that support tumour initiation and progression in the microenvironment of RDEB skin. Genetic loss of collagen VII causes RDEB and data from a recent animal model study show collagen VII reduces fibrosis in RDEB6,7.

Why investigate collagen VII and fibrosis in RDEB? – Why is it useful to understand experimental data? – What do we know about other EB subtypes?

Dr Nyström presents the highlights from his pre-recorded presentation of the session at EADV 2023.

Introduction – Introduction to collagen VII – Recessive dystrophic EB – Collagen VII and severe fibrosis – Collagen VII reduces fibrosis in EB – Microenvironment in RDEB skin

Meeting the challenge of wound healing

Future EB treatment landscape – Assessing data in treatment developments

Dr Lwin discusses translational research and how different investigational therapies, including gene therapy, cell therapy and repurposed or new drugs, aim to address wound healing. For example, systemic allogeneic mesenchymal stromal cells (MSCs) are currently being investigated in clinical trials for use in EB for the treatment of RDEB in children in the MissionEB trial8-10.

Dr Lwin discusses the potential role of cell therapies and gives her view of the potential challenges associated with future developments in EB treatment.

Incorporating B-VEC into practice – Potential role of investigational cell therapies

Dr Lwin and Dr Nyström discuss their opinion on potential clinical developments for EB in the next 10 years.

Dr Lwin presents the highlights from her pre-recorded presentation of the session at EADV 2023.

Introduction to wound healing – Wound healing in EB – Developing therapies for EB –Gene therapy – Cell therapy – Repurposed and new drugs


  1. Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner‐Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. British Journal of Dermatology. 2020;183(4):614-627.
  2. Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78.
  3. Filsuvez (birch bark extract) summary of product characteristics. 2022. Available at:
  4. U.S. Food & Drug Administration. FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa. Accessed 18 October.
  5. Filsuvez (birch bark extract) prescribing information. 2023. Available at:
  6. Gretzmeier C, Pin D, Kern JS, Chen M, Woodley DT, Bruckner-Tuderman L, et al. Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology. 2022;142(4):1094-1102.e1093.
  7. Nyström A, Bornert O, Kühl T, Gretzmeier C, Thriene K, Dengjel J, et al. Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa. Proc Natl Acad Sci U S A. 2018;115(4):E705-e714.
  8. Dieter K, Niebergall-Roth E, Daniele C, Fluhr S, Frank NY, Ganss C, et al. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Cytotherapy. 2023;25(7):782-788.
  9. Kiritsi D, Dieter K, Niebergall-Roth E, Fluhr S, Daniele C, Esterlechner J, et al. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI Insight. 2021;6(22).
  10. NHS. Great Ormond Street Hospital for Children. Clinical trial for children with rare skin condition gets underway. Accessed 18 October.
  11. Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. British Journal of Dermatology. 2022;188(1):12-21.
  12. Murrell D, L. Bruckner A, Sprecher E, Kiritsi D, Maher L, Cunningham T, Kern JS. BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study. British Journal of Dermatology. 2023;188(Supplement_4).
  13. Torres-Pradilla M, Álvarez E, Novoa M, Lozano I, Trujillo M. LB1791 Oleogel-S10 (birch bark extract) in dystrophic epidermolysis bullosa: A case series evaluating the impact on wound burden over 2 years. Journal of Investigative Dermatology. 2023;143(9):B34.

This content has been developed by EPG Health, for Medthority, in collaboration with Amryt Pharmaceuticals, the sponsor of the Industry Expert Hubs held at the European Academy of Dermatology and Venereology Congress in October 2023. This content is intended for healthcare professionals only. Amryt Pharmaceuticals is a wholly owned subsidiary of CHIESI SpA and the marketing authorisation holder for Oleogel-S10 in the EU and UK.

Job bag code: VV-MED-02197

DOP: February 2024